Becton, Dickinson and Company (NYSE:BDX) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 16.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,774,439 shares of the medical instruments supplier’s stock after purchasing an additional 532,999 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.30% of Becton, Dickinson and worth $917,753,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. Ironwood Wealth Management LLC. grew its holdings in Becton, Dickinson and by 384.9% in the fourth quarter. Ironwood Wealth Management LLC. now owns 611 shares of the medical instruments supplier’s stock valued at $153,000 after purchasing an additional 485 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Becton, Dickinson and by 0.3% in the 4th quarter. Victory Capital Management Inc. now owns 99,291 shares of the medical instruments supplier’s stock valued at $24,845,000 after purchasing an additional 318 shares during the last quarter. First Trust Advisors LP grew its stake in shares of Becton, Dickinson and by 298.3% during the 4th quarter. First Trust Advisors LP now owns 16,033 shares of the medical instruments supplier’s stock valued at $4,012,000 after buying an additional 12,008 shares during the period. Dynamic Advisor Solutions LLC increased its holdings in shares of Becton, Dickinson and by 16.7% during the 4th quarter. Dynamic Advisor Solutions LLC now owns 1,502 shares of the medical instruments supplier’s stock worth $376,000 after buying an additional 215 shares during the last quarter. Finally, Wade G W & Inc. acquired a new position in Becton, Dickinson and in the fourth quarter valued at $488,000. 83.51% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Claire Fraser sold 390 shares of the firm’s stock in a transaction dated Thursday, May 27th. The shares were sold at an average price of $241.36, for a total value of $94,130.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.76% of the stock is currently owned by corporate insiders.

A number of equities analysts have recently commented on BDX shares. Barclays assumed coverage on Becton, Dickinson and in a report on Monday, May 24th. They issued an “equal weight” rating and a $270.00 price objective on the stock. SVB Leerink decreased their price target on Becton, Dickinson and from $270.00 to $260.00 and set a “market perform” rating for the company in a report on Friday, May 7th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Becton, Dickinson and currently has an average rating of “Hold” and a consensus price target of $276.67.

NYSE BDX traded down $1.82 during trading hours on Friday, reaching $243.59. 10,961 shares of the company traded hands, compared to its average volume of 1,374,115. The stock has a 50 day simple moving average of $246.81. The stock has a market capitalization of $70.84 billion, a PE ratio of 43.67, a PEG ratio of 2.11 and a beta of 0.76. Becton, Dickinson and Company has a 12 month low of $219.50 and a 12 month high of $284.97. The company has a quick ratio of 1.32, a current ratio of 1.86 and a debt-to-equity ratio of 0.71.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Wednesday, May 5th. The medical instruments supplier reported $3.19 EPS for the quarter, topping the Zacks’ consensus estimate of $3.04 by $0.15. The business had revenue of $4.91 billion during the quarter, compared to the consensus estimate of $4.88 billion. Becton, Dickinson and had a return on equity of 15.53% and a net margin of 8.98%. The company’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same period last year, the firm earned $2.55 earnings per share. Analysts forecast that Becton, Dickinson and Company will post 12.81 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 30th. Shareholders of record on Wednesday, June 9th will be paid a dividend of $0.83 per share. The ex-dividend date of this dividend is Tuesday, June 8th. This represents a $3.32 annualized dividend and a yield of 1.36%. Becton, Dickinson and’s payout ratio is 32.55%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: What is the NASDAQ?

Want to see what other hedge funds are holding BDX? Visit to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with's FREE daily email newsletter.